Progeny’s new Genetic Testing Results (GTR) feature simplifies the process for genetic counselors and clinicians to track and modify genetic testing results from various labs in one application.  Detailed results and documents from tests ordered through Ambry Genetics are now automatically displayed.  We’ve also substantially increased the number of fields sent from Progeny to AmbryPort when placing orders.  Together, these improvements result in much less manual entry and a greatly improved user experience.  See a quick overview of our test ordering process and results tracking through Ambry below:


Users can also track results by selecting from a list of assays from other labs.  Gene lists are then auto-populated and can be modified quickly along with result classifications.  See a video of tracking test results for non-Ambry labs.

The GTR feature also empowers the clinician to use patient test results data when generating letters, querying data or tracking key reporting metrics.  Current users should update to Progeny or higher to access these new features and enhancements.

DELRAY BEACH, FLA., April 26th, 2017—Progeny Genetics LLC (Progeny), a leading risk modeling pedigree software for clinicians, announced today that Jamie L’Heureux, MS, CGC has been appointed to the role of Chief Executive Officer. For 20 years, Progeny has assisted healthcare providers with patient screening, risk analysis, order processing, clinical review, and letter generation.

Ms. L’Heureux brings over 12 years of experience in both research and clinical genetics as a Board Certified genetic counselor. She received her Master’s degree in Medical Genetics from the University of Cincinnati’s Genetic Counseling Training Program and began her career at the University of Iowa as a Research Coordinator for several international research projects.

Ms. L’Heureux’s strong background in software development includes implementing new laboratory information management systems and designing patient-facing Family History Questionnaires. For the past three years, Ms. L’Heureux served as Software Product Manager at Progeny, and was integral to development of Progeny’s letter generation feature and integrated risk models.

Read more…


At Progeny, we want every patient to receive the best possible diagnosis and treatment plan. We also value technology as a way to enhance the collection of family history data by clinicians.

In that spirit, we are excited to announce our latest innovation – the creation of an iPad app that gives doctors and clinicians the full Progeny experience while freeing them from being tied to a computer. The app enables on-the-go use of the full Progeny experience, with faster, easier pedigree creation and letter generation.

The app lets you review family history, create pedigrees and update your pedigrees in real-time from anywhere. In order to experience the app, users must upgrade to Progeny 10.

Learn more about the Progeny App and get the download…

Collecting family history is an important, but often time consuming, process when treating patients. At Progeny, we are constantly enhancing our pedigree technology to minimize the time it takes to collect, analyze and act on family history data.

We are excited to announce the release of Progeny 10. Built to save you time, Progeny 10 boasts an updated interface design for easy and fast navigation, in addition to these exciting new features:

  • Free iPad application: your easy on-the-go access to Progeny 10’s database.  View Details…
  • Letter Generation: Create your own custom consult notes, patient letters and reports pre-populated with your patient’s data.  View Details…
  • Updated database engine for faster speed and performance

Learn more about the benefits of Progeny 10 to your workflow, and make plans to upgrade today!

Pledges sizeable investment to collect, sequence, and share critical data to unlock true potential of the human genome, breaking the hoarding data mold that hinders medical progress

Aliso Viejo, CA – March 8, 2016 – Today, Ambry Genetics, a leader in clinical genetic diagnostics and genetics software solutions, took a radical step to fulfill the promise of unlocking the human genome by launching AmbryShare (, the largest free, disease-specific public database of human genome sequencing data. This action is a conservative first step to support the global medical research community and breaks the mold of data hoarding being done in academic and commercial organizations.

The first data released today are anonymized, aggregated data of 10,000 human genomes (exomes) focused on hereditary breast and ovarian cancer.  Ambry Genetics has already identified 10-fold more genes implicated in these conditions than previously known to the public, broadening understanding and potentially opening up more drug targets than from any single data release in history.  The company also is committed to continuing this effort to sequence genomes and release the data for all of its consented and de-identified patient samples, potentially contributing data from almost 200,000 genomes annually based on projections from its current sample volumes, and profoundly impacting the collective understanding of the genetics behind all human disease.

Read more…